Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success

Fierce Biotech·Dec 18

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Takeda is planning an FDA filing for its psoriasis treatment zasocitinib, a rival to Sotyktu, after the drug showed success in phase 3 trials. The treatment, a TYK2 blocker, reportedly outperformed Sotyktu in a head-to-head trial, with some outlets describing the results as "best-in-class". The company's plans for FDA filing are expected to move forward based on the positive phase 3 data.

Full coverage

Takeda’s oral TYK2 blocker outperforms Sotyktu in PsO trial

Clinical Trials Arena·Jun 12

Fierce Pharma Asia—Daiichi ADC's 1st-line nod, trial deaths; Takeda's TYK2 trial win

Fierce Pharma·Dec 19

Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial

Reuters·Jun 11

Takeda clears path to FDA with phase 3 data on $4B psoriasis bet

Fierce Biotech·Mar 28

Takeda plans filings for Sotyktu rival on new psoriasis data

pharmaphorum·Dec 18

Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data

BioSpace·Dec 19

Takeda’s zasocitinib meets phase III psoriasis endpoints

BioWorld News·Jan 8

Takeda Drug From $4B Deal Succeeds in Two Pivotal Plaque Psoriasis Trials

MedCity News·Dec 18

View original report at Fierce Biotech ↗

Fetching the latest headlines…